Severe hypoglycemia with trastuzumab: An unseen adverse event

CC BY-NC-ND 4.0 · South Asian J Cancer 2019; 08(03): 149
DOI: 10.4103/sajc.sajc_400_18

Letter to the Editor

B. P. Amrith

Department of Medical Oncology, Rajiv Gandhi Cancer Institute and Research Centre, New Delhi, India

,

Parveen Jain

Department of Medical Oncology, Rajiv Gandhi Cancer Institute and Research Centre, New Delhi, India

,

Krushna A. Chaudhari

Department of Medical Oncology, Rajiv Gandhi Cancer Institute and Research Centre, New Delhi, India

,

Mansi Sharma

Department of Medical Oncology, Rajiv Gandhi Cancer Institute and Research Centre, New Delhi, India

,

Ullas Batra

Department of Medical Oncology, Rajiv Gandhi Cancer Institute and Research Centre, New Delhi, India

References
1 Hudis CA. Trastuzumab – Mechanism of action and use in clinical practice. N Engl J Med 2007;357:39-51.
2 FDA Label-Trastuzumab. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/1998/trasgen092598lb.pdf. [Last accessed on 2018 Nov 15].
3 Herceptin and Hypoglycemia – From FDA Reports, eHealthME; November, 2018. Available from: https://www.ehealthme.com/ds/herceptin/hypoglycemia. [Last accessed on 2018 Nov 15].